Q4 2024 Biotest AG Earnings Call Transcript
Good morning, ladies and gentlemen. Welcome to our full year 2024 results. With me are Peter Janssen, our CEO; and Martin Möller, our former CFO. And we would like to take a look now at our last year's number and, of course, also at first on the ad hoc announcement that was just sent out this morning.
With this, I'd like to hand over to Peter.
Yes. Also from my side, good morning, everybody. Good morning, ladies and gentlemen. I am going to talk about the numbers in a minute, but first wanted to address the ad hoc release about the delisting.
I want to give you a little bit of background behind the rationale. So we are indeed considering a delisting of ordinary and preference shares. This is based on strategic priorities for us, also the financing options we have and the regulatory obligations. I'll explain in a few words. So Grifols, you know, holds most of the voting rights of Biotest and is not supporting us in any capital increases or bond issuances.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
